Navigation Links
Institut Paoli Calmettes and Ipsogen Presented a New Study Supporting the Pivotal Role of Tumor Grade in Chemotherapy Prescription at the 32nd Annual San Antonio Breast Cancer Symposium
Date:12/21/2009

MARSEILLE, France, Dec. 21 /PRNewswire/ -- Ipsogen SA (Alternext: ALIPS) today announced that a new study confirming the pivotal role of tumor grade in chemotherapy prescription has been presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), December 9-13, 2009.

The study was conducted at Institut Paoli Calmettes (IPC) Cancer Centre, Marseille, France. Using the centre database and a classification tree method, it retrospectively examined the tumor and patient characteristics driving prescription of adjuvant chemotherapy for 5854 early stage node negative (M-/N-), invasive breast cancer (IBC) patients treated between 1999 and 2005.

The study results indicate that tumor grade is the most contributive factor for adjuvant chemotherapy in N-/M- IBC, together with tumor size. Hierarchy of factors driving chemotherapy decision is remarkably stable over time, despite the progressive availability of new pathologic indicators over time.

"These new findings further support the value of Genomic Grade -a tool to refine tumor grading by resolving intermediate histologic grade 2 tumors in which indication of chemotherapy is a clinical challenge -- for treatment decision making. Integrated in currently validated treatment algorithms using tumor grade, the Genomic Grade could contribute to a more individualized chemotherapy strategy in Invasive Breast Cancer," comments Helene Peyro-Saint-Paul, Ipsogen Chief Medical Officer.

The study was presented at Poster Session 2, Friday, Dec 11, 2009, abstract # 2089:

Title: Real-life implementation of treatment guidelines for adjuvant chemotherapy in invasive breast cancer: retrospective analysis of a large single centre 10-year database.

Jean-Marie Boher, Jean-Marc Extra, Jacques Camerlo, Carole Tarpin, Emmanuelle Charaffe-Jauffret, Eric Lambaudie, Agnes Tallet, Helene Peyro-Saint-Paul, Patrice Viens

About IPSOGEN

Ipsogen develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists' decisions along their complex therapeutic path. With more than 70 references already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. As for leukemia, Ipsogen's goal is to provide diagnostic information that was not available until now. Ipsogen is also a partner of choice for biopharmaceutical companies committed to the development of 'companion diagnostic' tests.

Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly skilled multidisciplinary team in France and the USA, Ipsogen is striving to become the leader in molecular profiling of cancers. It continues its efforts to identify develop and commercialize diagnostic tests that will become standard references and will have a significant impact on patients, medical professionals and society. Ipsogen employed 70 people as of June 30, 2009. Its headquarters are located in Marseille, France. The company also has a subsidiary, Ipsogen Inc., in New Haven, CT, USA.

For more information, visit: www.ipsogen.com

SOURCE Ipsogen SA


'/>"/>
SOURCE Ipsogen SA
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property
2. Dyadic International Extends Collaboration With The Scripps Research Institute
3. YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
4. Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards
5. Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases
6. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
7. Gen-Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts
8. Lupus Research Institute: Benlysta(TM) Trial Results in an Historic Research Breakthrough and Victory for People With Lupus
9. Novocell Receives a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes
10. Schulman Associates IRB Establishes an Institutional Review Board in Canada
11. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):